Lọc theo
Focal therapy of significant localized prostate cancer associated with a magnetic resonance imaging (MRI) lesion using bipolar radiofrequency appears effective in ablating cancer, with low rates of genitourinary and rectal side effects, according to a study.
An association exists between magnetic resonance imaging (MRI) findings of localized prostate cancer and clinically relevant long-term oncologic outcomes, a study has found.
Treatment with 100-mg sildenafil appears to be the best strategy to improve erectile function recovery rates after radical prostatectomy, suggests a study. However, the on-demand dose of phosphodiesterase-5 (PDE5) inhibitors does not appear to be any better than placebo and must therefore not be considered as a penile rehabilitation strategy.
Prostate cancer seems to have no long-term adverse effects on survivors’ sexual, genitourinary, and general quality of life, a recent study has found.
Consumption of a newly developed whole tomato‑based food supplement* (WTFS) led to improvements in lower urinary tract symptoms** (LUTS) and quality of life (QoL) in men with benign prostatic hyperplasia (BPH), a phase II Italian study has shown.
Around-the-clock administration of intravenous acetaminophen lowers postoperative pain and the need for emergency analgesia after robot-assisted radical prostatectomy, a recent study has shown.
In children, dehiscence, severe recurrent ventral curvature, and urethral strictures all aggravate the risk of reoperation after primary hypospadias repair, a recent study.
In the treatment of vasculogenic erectile dysfunction (ED), low-intensity extracorporeal shockwave therapy (Li-ESWT) is safe and effective for some patients, particularly those with mild-to-moderate ED, a study suggests.
Adding apalutamide (APA) to abiraterone acetate and prednisone (AAP) significantly extends radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with AAP only, according to the final analysis of the ACIS* trial presented at ASCO GU 2021.
In an updated analysis of the phase III POUT* trial presented at ASCO GU 2021, peri-operative chemotherapy continued to improve disease-free survival (DFS) compared with surveillance in patients with upper tract urothelial cancer (UTUC).
